Abstract
Aim:
(-)Stepholidine (SPD) is an active ingredient of the Chinese herb Stephania intermedia, which binds to the dopamine D1 and D2 like receptors. Biochemical, electrophysiological and behavioural experiments have provided strong evidence that SPD is both a D1 and a D2 antagonist, which could make SPD a unique antipsychotic drug. The present study aimed to investigate the antipsychotic properties of SPD in two animal models for schizophrenia.
Methods:
The effects of SPD, clozapine and haloperidol in increasing forelimb and hindlimb retraction time in the paw test and in reversing the apomorphine and MK801-induced disruption of prepulse inhibition was investigated.
Results:
In the paw test, clozapine and SPD increased the hindlimb retraction time, with only a marginal effect on the forelimb retraction time, whereas haloperidol potently increased both. In the prepulse inhibition paradigm, all three drugs reverse the apomorphine-induced disruption in prepulse inhibition, while none of the drugs could reverse the MK801-induced disruption. SPD even slightly, but significantly, potentiated the effects of MK801.
Conclusion:
The data show that SPD showed antipsychotic-like effects in both the prepulse inhibition paradigm and in the paw test. Moreover, the results of the paw test suggest that SPD has an atypical character with a relatively small potency to induce extrapyramidal side effects.
Similar content being viewed by others
Article PDF
References
Jin GZ . (-)-Tetrahydropalmatine and its analogues as new dopamine receptor antagonists. Trends Pharmacol Sci 1987; 8: 81–2.
Xu SX, Yu LP, Han YR, Chen Y, Jin GZ . Effects of tetrahydropro-toberberines on dopamine receptor subtypes in brain. Acta Pharmacol Sin 1989; 10: 104–10.
Sun BC, Jin GZ . Characteristics of (-)-stepholidine on the firing activity of substantia nigral dopamine neurons after repeated reserpine treatment. Biol Signals 1992; 1: 331–8.
Chiodo LA, Bunney BS . Typical and atypical neuroleptics: Differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 1983; 3: 1607–19.
White FJ, Wang RY . Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 1983; 211: 1054–6.
Skarsfeldt T . Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. Eur J Pharmacol 1995; 281: 289–94.
Zhang ZD, Jin GZ, Xu SX, Yu LP, Chen Y, Jiang FY, et al. Effects of l-stepholidine on the central nervous and cardiovascular systems. Acta Pharmacol Sin 1986; 7: 522–6.
Jin GZ, Huang KX, Sun BC . Dual actions of (-)-stepholidine on dopamine receptor subtypes after substantia nigra lesion. Neurochem Int 1992; 20 Suppl: 175S–8S.
Zou LL, Chen Y, Song YY, Jin GZ . Effect of (-)-stepholidine on serum prolactin level of female rats. Acta Pharmacol Sin 1996; 17: 311–4.
Dong ZJ, Guo X, Chen LJ, Han YF, Jin GZ . Dual action of (-)-stepholidine on the dopamine receptor mediated adenylate cy-clase activity in rat corpus striatum. Life Sci 1997; 61: 465–72.
Huang KX, Jin GZ . The antagonistic effects of tetrahydroproto-berberines on dopamine receptors: electrophysiological studies. Sci China B 1992; 35: 688–96.
Sun BC, Jin GZ . Effects of (-)-Stepholidine on firing activity of dopamine rneurons in ventral tegmental area of the rats. Acta Pharmacol Sin 1992; 13 395–9.
Dong ZJ, Chen LJ, Jin GZ, Creese I . GTP regulation of (-)-stepholidine binding to R(H) of D1 dopamine receptors in calf striatum. Biochem Pharmacol 1997; 54: 227–32.
Liu J, Guo X, Wang BC, Jin GZ . Increased phosphorylation of DARPP-32 by D1 agonistic action of l-stepholidine in the 6-OHDA-lesioned rat striatum. Acta Physiol Sin 1999; 51: 65–72.
Zhu ZT, Fu Y, Hu GY, Jin GZ . Modulation of medial prefrontal cortical D1 receptors on excitatory firing activity of nucleus accumbens neurons elicited by (-)-stepholidine. Life Sci 2000; 67: 1265–74.
Zhu ZT, Fu Y, Hu GY, Jin GZ . Electrophysiological study on biphasic firing activity elicted by D1 agonist-D2 antagonist action of (-)-stepholidine in nucleus accumbens. Acta Physiol Sin 2000; 52: 123–30.
Jin GZ, Zhu ZT, Fu Y . (-)-Stepholidine: a potential novel antipsychotic drug with dual D1 receptor agonist and D2 receptor antagonist actions. Trends Pharmacol Sci 2002; 23: 4–7.
Ellenbroek BA, Peeters BW, Honig WM, Cools AR . The paw test: a behavioural paradigm for differentiating between classical and atypical neuroleptic drugs. Psychopharmacology (Berl) 1987; 93: 343–8.
Cools AR, Prinssen EP, Ellenbroek BA . The olfactory tubercle as a site of action of neuroleptics with an atypical profile in the paw test: effect of risperidone, prothipendyl, ORG 5222, sertindole and olanzapine. Psychopharmacology (Berl) 1995; 119: 428–39.
Ellenbroek B, Cools AR . The Paw test: an animal model for neuroleptic drugs which fulfils the criteria for pharmacological isomorphism. Life Sci 1988; 42: 1205–13.
Ellenbroek BA . Treatment of schizophrenia: a clinical and pre-clinical evaluation of neuroleptic drugs. Pharmacol Ther 1993; 57: 1–78.
Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR . Pharmacological studies of prepulse inhibition models of sensorimo-tor gating deficits in schizophrenic patients: a decade in review. Psychopharmacology (Berl) 2001; 156: 117–54.
Swerdlow NR, Braff DL, Taaid N, Geyer MA . Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 1994; 51: 139–54.
Bast T, Zhang WN, Feldon J, White IM . Effects of MK801 and neuroleptics on prepulse inhibition: re-examination in two strains of rats. Pharmacol Biochem Behavior 2000; 67: 647–58.
Feifel D, Priebe K . The effects of subchronic haloperidol on intact and dizocilpine-disrupted sensorimotor gating. Psychopharmacology (Berl) 1999; 146: 175–9.
Johansson C, Jackson DM, Svensson L . The atypical antipsychotic, remoxipride, blocks phencyclidine-induced disruption of prepulse inhibition in the rat. Psychopharmacology (Berl) 1994; 116: 437–42.
Keith VA, Mansbach RS, Geyer MA . Failure of haloperidol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of startle. Biol Psychiatry 1991; 30: 557–66.
Varty GB, Higgins GA . Examination of drug-induced and isolation-induced disruptions of prepulse inhibition as models to screen antipsychotic drugs. Psychopharmacology (Berl) 1995; 122: 15–26.
Swerdlow NR, Bakshi V, Waikar M, Taaid N, Geyer MA . Seroquel, clozapine and chlorpromazine restore sensorimotor gating in ketamine-treated rats. Psychopharmacology (Berl) 1998; 140: 75–80.
Yamada S, Harano M, Annoh N, Nakamura K, Tanaka M . Involvement of serotonin 2A receptors in phencyclidine-induced disruption of prepulse inhibition of the acoustic startle in rats. Biol Psychiatry 1999; 46: 832–8.
Bakshi VP, Swerdlow NR, Geyer MA . Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther 1994; 271: 787–94.
Varty GB, Higgins GA . Reversal of dizocilpine-induced disruption of prepulse inhibition of an acoustic startle response by the 5-HT2 receptor antagonist ketanserin. Eur J Pharmacol 1995; 287: 201–5.
Wiley JL . Clozapine's effects on phencyclidine-induced disruption of prepulse inhibition of the acoustic startle response. Pharmacol Biochem Behav 1994; 49: 1025–8.
Ellenbroek BA, Liegeois JF, Bruhwyler J, Cools AR . Effects of JL13, a pyridobenzoxazepine with potential atypical antipsychotic activity, in animal models for schizophrenia. J Pharmacol Exp Ther 2001; 298: 386–91.
Swerdlow NR, Geyer MA, Braff DL . Neural circuit regulation of prepulse inhibition of startle in the rat: Current knowledge and future challenges. Psychopharmacology (Berl) 2001; 156: 194–215.
Geyer MA, Ellenbroek B . Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 1071–9.
Ellenbroek BA, Lubbers LJ, Cools AR . Activity of “seroquel” (ICI 204,636) in animal models for atypical properties of antipsychotics: a comparison with clozapine. Neuropsychopharmacology 1996; 15: 406–16.
Ellenbroek BA, Prinssen EP, Cools AR . The role of serotonin receptor subtypes in the behavioural effects of neuroleptic drugs. A paw test study in rats. Eur J Neurosci 1994; 6: 1–8.
Jin GZ, Sun BC . (-)Stepholidine and its analogs act on brain dopamine receptors. Prog Nat Sci 1995; 5: 55–63.
Ellenbroek BA, Artz MT, Cools AR . The involvement of dopamine D1 and D2 receptors in the effects of the classical neuroleptic haloperidol and the atypical neuroleptic clozapine. Eur J Pharmacol 1991; 196: 103–8.
Prinssen EP, Ellenbroek BA, Stamatovic B, Cools AR . The effects of haloperidol and raclopride in the paw test are influenced similarly by SCH 39166. Eur J Pharmacol 1993; 231: 275–80.
Mansbach RS . Effects of NMDA receptor ligands on sensorimotor gating in the rat. Eur J Pharmacol 1991; 202: 61–6.
Mansbach RS, Geyer MA . Parametric determinants in pre-stimulus modification of acoustic startle: interaction with ketamine. Psychopharmacology (Berl) 1991; 105: 162–8.
Zhang XX, Sun BC, Jin GZ . Atypical neuroleptic properties of (-)-stepholidine. Sci China B 1997; 40: 531–9.
Sawaguchi T, Goldman-Rakic PS . D1 dopamine receptors in the prefrontal cortex: involvement in working memory. Science 1991; 251: 947–50.
Granon S, Passetti F, Thomas KL, Dalley JW, Everitt BJ, Robbins TW . Enhanced and impaired attentional performance after infusion of D1 dopaminergic receptor agents into the rat prefrontal cortex. J Neurosci 2000; 20: 1208–15.
Knable MB, Hyde TM, Murray AM, Herman MM, Kleinman JE . A postmortem study of frontal cortical dopamine D 1 receptors in schizophrencs, psyciatric controls, and normal controls. Biol Psychiatry 1996; 40: 1191–9.
Hess EJ, Bracha HS, Kleinman JE, Creese I . Dopamine receptor subype imbalance in schizophrenia. Life Sci 1987; 40: 1487–97.
Albert KA, Hemmings HC Jr, Adamo AI, Potkin SG, Akbarian S, Sandman CA . Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia. Arch Gen Psychiatry 2002; 59: 705–12.
Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y . Prefrontal dopamine D 1 receptors and working memory in schizophrenia. J Neurosci 2002; 22: 3708–19.
Author information
Authors and Affiliations
Corresponding author
Additional information
Project supported by the National Basic Research Program 973 from Ministry of Science and Technology in China (No 2003 CB515401).
Rights and permissions
About this article
Cite this article
Ellenbroek, B., Zhang, Xx. & Jin, Gz. Effects of (-)stepholidine in animal models for schizophrenia. Acta Pharmacol Sin 27, 1111–1118 (2006). https://doi.org/10.1111/j.1745-7254.2006.00365.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2006.00365.x
Keywords
This article is cited by
-
Significantly different effects of tetrahydroberberrubine enantiomers on dopamine D1/D2 receptors revealed by experimental study and integrated in silico simulation
Journal of Computer-Aided Molecular Design (2019)
-
(-)-Stepholidine is a potent pan-dopamine receptor antagonist of both G protein- and β-arrestin-mediated signaling
Psychopharmacology (2015)
-
The antipsychotic potential of l-stepholidine—a naturally occurring dopamine receptor D1 agonist and D2 antagonist
Psychopharmacology (2008)